Molecular structure of Rocaglamide, CAS Number: 84573-16-0
Rocaglamide (CAS 84573-16-0)
See product citations (4)
Alternate Names:
Rocaglamide is also known as GNF-Pf-1749.
Application:
Rocaglamide is an immunosuppressant tetrahydrobenzofuran compound and an inhibitor of NFκB activity.
CAS Number:
84573-16-0
Purity:
≥95%
Molecular Weight:
505.56
Molecular Formula:
C29H31NO7
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Rocaglamide is an immunosuppressant. It is known to potently and almost completely inhibit the activation of NF-κB, a protein complex that controls DNA transcription, in T cells. It has been found to suppress the production of cytokine and inhibit NF-AT in peripheral blood T cells. Unlike the immunosuppressant cyclosporin A, rocaglamide does not inhibit the activity of calcineurin phosphatase. It has been found to induce apoptosis in leukemia cells through the modulation of protein kinase activities that are activated by mitogen. Derivatives of rocaglamide display insecticidal activity.
Rocaglamide (CAS 84573-16-0) References
- Cyclopenta[b]benzofurans from Aglaia species with pronounced antifungal activity against rice blast fungus (Pyricularia grisea). | Engelmeier, D., et al. 2000. J Agric Food Chem. 48: 1400-4. PMID: 10775404
- Insecticidal rocaglamide derivatives from Aglaia spectabilis (Meliaceae). | Schneider, C., et al. 2000. Phytochemistry. 54: 731-6. PMID: 11014256
- Rocaglamide derivatives are potent inhibitors of NF-kappa B activation in T-cells. | Baumann, B., et al. 2002. J Biol Chem. 277: 44791-800. PMID: 12237314
- Rocaglamide derivatives are immunosuppressive phytochemicals that target NF-AT activity in T cells. | Proksch, P., et al. 2005. J Immunol. 174: 7075-84. PMID: 15905551
- The traditional Chinese herbal compound rocaglamide preferentially induces apoptosis in leukemia cells by modulation of mitogen-activated protein kinase activities. | Zhu, JY., et al. 2007. Int J Cancer. 121: 1839-46. PMID: 17565740
- Rocaglamide sensitizes leukemic T cells to activation-induced cell death by differential regulation of CD95L and c-FLIP expression. | Zhu, JY., et al. 2009. Cell Death Differ. 16: 1289-99. PMID: 19373244
- Rocaglamide and a XIAP inhibitor cooperatively sensitize TRAIL-mediated apoptosis in Hodgkin's lymphomas. | Giaisi, M., et al. 2012. Int J Cancer. 131: 1003-8. PMID: 21952919
- Evidence for a functionally relevant rocaglamide binding site on the eIF4A-RNA complex. | Sadlish, H., et al. 2013. ACS Chem Biol. 8: 1519-27. PMID: 23614532
- Progress in the total synthesis of rocaglamide. | Cai, XH., et al. 2011. ISRN Org Chem. 2011: 239817. PMID: 24052818
- Rocaglamide, silvestrol and structurally related bioactive compounds from Aglaia species. | Pan, L., et al. 2014. Nat Prod Rep. 31: 924-39. PMID: 24788392
- Rocaglamide overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells by attenuating the inhibition of caspase-8 through cellular FLICE-like-inhibitory protein downregulation. | Luan, Z., et al. 2015. Mol Med Rep. 11: 203-11. PMID: 25333816
- Chinese herb derived-Rocaglamide A is a potent inhibitor of pancreatic cancer cells. | Wang, B., et al. 2016. Am J Transl Res. 8: 1047-54. PMID: 27158390
- Rocaglamide enhances NK cell-mediated killing of non-small cell lung cancer cells by inhibiting autophagy. | Yao, C., et al. 2018. Autophagy. 14: 1831-1844. PMID: 29969944
- Sensitization of renal carcinoma cells to TRAIL-induced apoptosis by rocaglamide and analogs. | Nalli, AD., et al. 2018. Sci Rep. 8: 17519. PMID: 30504817
- PHB2 (prohibitin 2) promotes PINK1-PRKN/Parkin-dependent mitophagy by the PARL-PGAM5-PINK1 axis. | Yan, C., et al. 2020. Autophagy. 16: 419-434. PMID: 31177901
- Rocaglamide and silvestrol: a long story from anti-tumor to anti-coronavirus compounds. | Schulz, G., et al. 2021. Nat Prod Rep. 38: 18-23. PMID: 32699874
- Rocaglamide promotes the infiltration and antitumor immunity of NK cells by activating cGAS-STING signaling in non-small cell lung cancer. | Yan, X., et al. 2022. Int J Biol Sci. 18: 585-598. PMID: 35002511
- Rocaglamide Prolonged Allograft Survival by Inhibiting Differentiation of Th1/Th17 Cells in Cardiac Transplantation. | Dai, C., et al. 2022. Oxid Med Cell Longev. 2022: 2048095. PMID: 35087613
Inhibitor of:
(eukaryotic translation initiation factor) eIF, (eukaryotic translation initiation factor) eIF1, (eukaryotic translation initiation factor) eIF2, (eukaryotic translation initiation factor) eIF5, β-defensin 14, 2310057J18Rik, 4931406C07Rik, 9130206N08Rik, A630018P17Rik, ACD, ACOT7, ALG1L, arginase I, ARH, ARL8A, ARMC3, Atg2A, ATP5L, ATPBD1B, BASE, Blood Group N antigen, BRP44, BTF3L2, BUD13, BXDC1, C14orf124, C15orf44, C1orf83, C20orf78, C4BPα, C78339, C9orf72, CGNL1, CHMP1A, CHMP3, CIP29, CMPK, CNOT8, CPEB, CPSF2, CPSF3, CPSF3L, CPSF4, CPSF4L, CRELD1, CRSP150_CRSP2, CstF-64, CTGLF3, cyclin O, DBR1, DDX27, DDX28, DDX30, DDX39, DDX3L, DDX40, DDX46, DDX47, DDX56, DDX57, DDX59, DENR, DGCR8, Dim1, DPH2, DUB3, DUX4L15, Dynlt1c, E4F1, EF-1δ, EG666806, eIF1, eIF1AY, eIF2Bδ, eIF3β, eIF3δ, eIF3ε, eIF3M, eIF4B, eIF5A1, EVPLL, EXOSC1, FARP2, FASTKD5, FLJ20433, FLRT3, FOXD4L3, FRG2B, FTCD, FXR1, FXR2, Gγ 1, Gγ 7, GALK1, GEFT, GGA2, GPI-PLD, GRHL3, GRINL1A, GYKL1, H1FOO, H2-M10.4, H2-M9, H2al3, HAX-1, Hbb-bh1, hCG_2015138, hCG_2024596, hDcp2, HemT-1, HEXIM1, Histatin 1, Histone cluster 1 H2AN, Histone cluster 2 H3B, Histone cluster 2 H4A, HMG-14, HMG20A, HMX3_Hmx3, hnRNP A2/B1, hnRNP A3, hnRNP B1, hnRNP CL1, hnRNP D0, hnRNP H′/hnRNP H2, hnRNP J, hnRNP M, hnRNP R, IFITM6, ILDR2, ILPIP, INO80B, IQCF3, IQSEC1, ITPase, Iws1, K230010J24Rik, Keratin 42, KIAA1244, Klkb1, KLRI1, KRR1, KRTAP11-1, KRTAP16-10, KRTAP19-8, KRTAP9-L3, Ku, Kua-Uev, LARP4, LARP5, LARP7, LAS1L, LCRISP2, Lipocalin-3, Liprin α1, LOC100039269, LOC100039346, LOC100039560, LOC100040299, LOC100040500, LOC100040722, LOC100040857, LOC100040923, LOC100041102, LOC100041177, LOC151174, LOC283547, LOC338588, LOC645967, LOC646762, LOC730005, LRIG3, LRRC55, LRWD1, MAGOHB, MAGP-2, MAP LC3α, MCAF2, Med11, Mina53, Mndal, MOCS1, MPP10, MPZL1, MREG, MTP18, Munc13-2, MUT, NDUFB10, NETO2, NF kappa B, NGP1, NHPX, NMD3, NNP-1, Nocturnin, NOL11, NOP16, NOPAR, NOSTRIN, nRNP, NXF7, OBFC1, Olfr239, p73α, PABPC4, PABPC4L, pancpin, PCDHA5, PE-1, PLGLA1, PLGLB2, POLR2J1, POLR2J2, POM121, POMZP3, Positive cofactor 4, POTEJ, PRAMEF19, PRKRIP1, Prohibitin, Prohibitin 2, quiescin Q6, RAET1G, Ran BP-6, RASAL3, RBM19, RBM27, RBM28, RBM29, RBM32A, RBM35A, RBM38, RBMY1D, RFXDC2, RhC, Rheb, RMI1, RPL22L1, RPL6, RPL7A, Rpp40, RQCD1, RRP9, RSL1D1, SCO-spondin, Sec31, Set1B, SFI1, SKIV2L, SMF_Hmgxb3, SMG7, SNAP 29, SPIN90, SPT6, Srb7, SRGAP2P1, STAU2, Supt4h2, SWI/SNF-B, SWI5, Swiprosin-1, synphilin-1, TAF I p110_TAF I p95, TAF II p100, TAF II p130, TAF II p135, TAF II p150, TAF II p170, TARSL2, TASK-2, TCEA2, TCEAL3, TCEAL5, TCEAL6, TFEC, TFIID, TFIIIC102, THOC4, TIA1, Tif, TMCO3, TMEM106B, TMEM191B, TMEM50B, TRABD, TRAP-α, Twinfilin-1, U2 snRNP B′′, UTP14A, UTP23, VASA, vezatin, WBSCR22, WBSCR27, XRN2, ZCCHC7, ZDHHC9, ZFP36L3, ZGPAT, ZNF265, ZNF580, and ZNF593.Activator of:
CstF-50, DDX18, DDX54, eIF4AI, eIF4AIII, eIF4B, EXOSC5, LOC100041244, MRT4, MyoD, POLR2I, Ribosomal Protein L26L1, RRP15, and STAU1.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Rocaglamide, 100 µg | sc-203241 | 100 µg | $270.00 | |||
Rocaglamide, 1 mg | sc-203241A | 1 mg | $465.00 | |||
Rocaglamide, 5 mg | sc-203241B | 5 mg | $1607.00 | |||
Rocaglamide, 10 mg | sc-203241C | 10 mg | $2448.00 | |||
Rocaglamide, 25 mg | sc-203241D | 25 mg | $5239.00 |